The Dealreporter is reporting that the FSTX deal is not going through due to CIFUS delaying action, citing sources close to InvoX, the company buying FSTX. The stock is down well below $4/share. (This will be the final nail in my coffin.) FSTX has four drugs in clinical trials, so maybe some company will step up to the table. But FSTX is very short on cash.
If, by chance, the report is wrong and allows certain investors to get in cheap before the buyout at $7.11 on the 31st, then this will be one of biggest (coolest?) scams in all time.
I’m trying to get in touch with management. Stock down 40%.
Bladerunner
Market Data 
Markets 
AI
